Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2578305 | 1.00 | SCN1A (0.41) | SCN1ASCN2ASCN3ACA12CA1 | |
| SCHEMBL3810670 | 0.89 | DRD2 (0.40) | SCN1ASCN2ASCN3ACA12CA1 | |
| Citric Acid SCHEMBL2469191 | 0.87 | MAPT (0.41) | SCN1ASCN2ASCN3AKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL15392160 | 0.87 | ALDH1A1 (0.40) | SCN1ASCN2ASCN3ACA12CA1 | |
| SCHEMBL16552783 | 0.87 | ALDH1A1 (0.40) | SCN1ASCN2ASCN3ACA12CA1 | |
| Aspirin SCHEMBL2472612 | 0.86 | KDM4E (0.51) | SCN1ASCN2ASCN3AHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL2578551 | 0.86 | HPGD (0.36) | SCN1ASCN2ASCN3ACA12CA1 | |
| SCHEMBL2590578 | 0.84 | HPGD (0.37) | SCN1ASCN2ASCN3ACA12CA1 | |
| SCHEMBL3807262 | 0.84 | CA12 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11642932 | 0.81 | SCN1A (0.58) | SCN1ASCN2ASCN3ANPC1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | claimed |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD | 2019-05-16 | — | — | US | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| EP-4245752-A2 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | Techfields Inc (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | TECHFIELDS PHARMA CO., LTD (CN) | 2023-07-27 | — | — | US | disclosed |
| US-11541029-B2 | High penetration compositions and their applications | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-01-03 | — | — | US | disclosed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | disclosed |
| EP-2610242-A1 | Positively charged water-soluble prodrugs of aspirin | Techfields Biochem Co. Ltd (CN) | 2013-07-03 | — | — | EP | disclosed |
| EP-2610242-A1 | Positively charged water-soluble prodrugs of aspirin | Techfields Biochem Co. Ltd (CN) | 2013-07-03 | — | — | EP | disclosed |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2011-11-03 | — | — | US | disclosed |
| EP-2370406-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | Yu, Chongxi (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010065936-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | YU CHONGXI (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| EP-2038251-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ASPIRIN | Techfields Biochem Co. Ltd (CN) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008007171-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ASPIRIN | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SCN1A 2357/4885SCN2A 2829/4885SCN3A 2213/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | SCN1A 3747/4885SCN2A 4027/4885SCN3A 3125/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SCN1A 2357/4885SCN2A 2829/4885SCN3A 2213/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SCN1A 2357/4885SCN2A 2829/4885SCN3A 2213/4885 |
| US-20110269689-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC19A1, HIRA, SLC43A1 | SCN1A 355/4885SCN2A 426/4885SCN3A 341/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SCN1A 2357/4885SCN2A 2829/4885SCN3A 2213/4885 |
| US-11541029-B2 | High penetration compositions and their applications | SLC19A1, HIRA, SLC43A1 | SCN1A 355/4885SCN2A 426/4885SCN3A 341/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | SCN1A 2357/4885SCN2A 2829/4885SCN3A 2213/4885 |
| US-20230233516-A1 | HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS | SLC5A7, SLC19A1, SLC43A1 | SCN1A 343/4885SCN2A 447/4885SCN3A 487/4885 |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | CPA3, HCAR2, HRH4 | SCN1A 3330/4885SCN2A 3440/4885SCN3A 2892/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SCN1A 846/4885SCN2A 918/4885SCN3A 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.